Ocumension Therapeutics

SEHK:1477 Rapporto sulle azioni

Cap. di mercato: HK$4.4b

Ocumension Therapeutics Performance dei guadagni passati

Il passato criteri di controllo 0/6

Ocumension Therapeutics has been growing earnings at an average annual rate of 50.6%, while the Pharmaceuticals industry saw earnings growing at 5.7% annually. Revenues have been growing at an average rate of 61.3% per year.

Informazioni chiave

50.6%

Tasso di crescita degli utili

92.5%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore5.6%
Tasso di crescita dei ricavi61.3%
Rendimento del capitale proprio-11.7%
Margine netto-104.0%
Ultimo aggiornamento sui guadagni30 Jun 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

With Ocumension Therapeutics (HKG:1477) It Looks Like You'll Get What You Pay For

Sep 21
With Ocumension Therapeutics (HKG:1477) It Looks Like You'll Get What You Pay For

Analysts Are Upgrading Ocumension Therapeutics (HKG:1477) After Its Latest Results

Aug 15
Analysts Are Upgrading Ocumension Therapeutics (HKG:1477) After Its Latest Results

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Ocumension Therapeutics' (HKG:1477) CEO For Now

Jun 13
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Ocumension Therapeutics' (HKG:1477) CEO For Now

Ocumension Therapeutics' (HKG:1477) P/S Still Appears To Be Reasonable

Apr 29
Ocumension Therapeutics' (HKG:1477) P/S Still Appears To Be Reasonable

Here's Why We're Not Too Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Situation

Mar 14
Here's Why We're Not Too Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Situation

Some Analysts Just Cut Their Ocumension Therapeutics (HKG:1477) Estimates

Aug 29
Some Analysts Just Cut Their Ocumension Therapeutics (HKG:1477) Estimates

We're Hopeful That Ocumension Therapeutics (HKG:1477) Will Use Its Cash Wisely

Jul 13
We're Hopeful That Ocumension Therapeutics (HKG:1477) Will Use Its Cash Wisely

Is Ocumension Therapeutics (HKG:1477) Trading At A 48% Discount?

Jun 02
Is Ocumension Therapeutics (HKG:1477) Trading At A 48% Discount?

We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate

Jan 20
We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate

We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate

Sep 27
We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate

Could The Ocumension Therapeutics (HKG:1477) Ownership Structure Tell Us Something Useful?

Jan 23
Could The Ocumension Therapeutics (HKG:1477) Ownership Structure Tell Us Something Useful?

Ripartizione dei ricavi e delle spese

Come Ocumension Therapeutics guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.


Storia dei guadagni e delle entrate

SEHK:1477 Ricavi, spese e utili (CNY Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
30 Jun 24310-323409109
31 Mar 24278-351416117
31 Dec 23246-380423124
30 Sep 23227-399429141
30 Jun 23208-418435159
31 Mar 23184-411405172
31 Dec 22159-403374184
30 Sep 22124-393340180
30 Jun 2290-383305175
31 Mar 2273-322279172
31 Dec 2156-260254169
30 Sep 2144-426237194
30 Jun 2132-593220220
31 Mar 2123-1,429252200
31 Dec 2013-2,265284180
30 Sep 208-2,540242150
30 Jun 202-2,816200121
31 Mar 201-2,064130110
31 Dec 190-1,3126099

Guadagni di qualità: 1477 is currently unprofitable.

Margine di profitto in crescita: 1477 is currently unprofitable.


Flusso di cassa libero e analisi degli utili


Analisi della crescita degli utili nel passato

Andamento degli utili: 1477 is unprofitable, but has reduced losses over the past 5 years at a rate of 50.6% per year.

Accelerare la crescita: Unable to compare 1477's earnings growth over the past year to its 5-year average as it is currently unprofitable

Guadagni vs Settore: 1477 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.4%).


Rendimento del capitale proprio

ROE elevato: 1477 has a negative Return on Equity (-11.66%), as it is currently unprofitable.


Rendimento delle attività


Rendimento del capitale investito


Scoprire le aziende con forti performance passate